Thrombotic microangiopathies in bone marrow and organ transplant patients

Journal of Clinical Apheresis

Volumn 17, Issue 3, 2002, Pages 118-123

  McLeod, Bruce C ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

Bone marrow transplantation; Hemolytic uremic syndrome; Solid organ transplantation; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura

Indexed keywords

BONE MARROW TRANSPLANTATION; CLINICAL PRACTICE; CONFERENCE PAPER; ENDOTHELIUM INJURY; HEMOLYTIC UREMIC SYNDROME; HUMAN; ORGAN TRANSPLANTATION; PLASMAPHERESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

BONE MARROW TRANSPLANTATION; HEMOLYTIC-UREMIC SYNDROME; HUMANS; ORGAN TRANSPLANTATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 0036399814     PISSN: 07332459     EISSN: None     Source Type: Journal    
DOI: 10.1002/jca.10030     Document Type: Conference Paper

References (46)

1. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: A hitherto undescribed disease. Proc NY Pathol Soc 1924;24:21-24.
2. Gasser C, Gautier E, Steck A, Siebenmann RE, Dechslin R. Hämolytisch-urämische Syndrome: Bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien. Schweiz Med Wochenschr 1955;85:905-909.
3. Remuzzi G. HUS and TTP: Variable expression of a single entity. Kid Int 1987;32:292-308.
4. Murgo AJ. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol 1987;24:161-177.
5. Gordon LI, Kwaan HC, Rossi EC. Deleterious effects of platelet transfusions and recovery thrombosis in patients with thrombotic microangiopathy. Semin Hematol 1987;24:194-201.
6. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96:1223-12229.
7. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-1584.
8. Tsai H, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594.
9. Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997;89:3097-3103.
10. Furlan M, Lämmle B. Haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura: new insights into underlying biochemical mechanisms. Nephrol Dial Transplant 2000;15:1112-1114.
11. Veyradier A, Obert B, Houllier A, Meyer D, Girma J-P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001;98:1765-1772.
12. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994;14:495-504.
13. Roy V, Rizvi MA, Vesely SK, George JN. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 2001;27:641-646.
14. Zeigler ZR, Shadduck RK, Nemunaitis J, Andrews DF, Rosenfeld CS. Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant 1995;15:247-253.
15. Schriber JR, Jerzig GP. Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997;34:126-133.
16. Paquette RL, Tran L, Landaw EM. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis. Bone Marrow Transplant 1998;22:351-357.
17. Jacopino P, Pucci G, Arese W, et al. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Bone Marrow Transplant 1999;24:47-51.
18. Fuge R, Bird JM, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 2001;113:58-64.
19. van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenia purpura. Blood 1999;93:3798-3802.
20. Zeigler Z, Kelton J, Moore J, et al. Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura. Bone Marrow Transplant 1999;24:641-645.
21. Natazuka T, Kajimoto K, Ogawa R, et al. Coagulation abnormalities and thrombotic microangiopathy following bone marrow transplantation from HLA-matched unrelated donors in patients with hematological malignancies. Bone Marrow Transplant 1998;21:815-819.
22. Anthony MT, Zeigler ZR, Lister J, et al. Plasminogen activator inhibitor (PAI-1) antigen levels in primary TTP and secondary TTP post-bone marrow transplantation. Am J Hematol 1998;59:9-14.
23. Plews DE, Turner ML, Wallace WH. Plasma exchange as successful treatment of thrombotic thrombocytopenic purpura post autologous bone marrow transplant in a child. Bone Marrow Transplant 2000;25:679-680.
24. Milone J, Napal J, Bordone J, Etchegoyen O, Morales V. Complete response in severe thrombotic microangiopathy post bone marrow transplantation after multiple plasmaphereses. Bone Marrow Transplant 1998;22:1019-1021.
25. Kolker O, Sviri S, Linton DM, et al. Plasmapheresis for thrombotic thrombocytopenic purpura following bone marrow transplantation. Acta Haematol 2001;105:156-158.
26. Sarode R, McFarland JG, Flomenber N, et al. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 1995;16:271-275.
27. Lahlou A, Lang P, Charpentier B, et al. Hemolytic uremic syndrome. Recurrence after renal transplantation. Groupe Cooperatif de I'lle-de-France (GCIF). Medicine 2000;79:90-102.
28. Mihatsch MJ, Kyo M, Morozumi K, et al. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol 1998;49:356-363.
29. Kohler TR, Tilney. Microangiopathic hemolytic anemia associated with hyperacute rejection of a kidney allograft. Transplant Proc 1982;15:444-447.
30. Mor E, Lustig S, Tovar A, et al. Thrombotic microangiopathy early after kidney transplantation: hemolytic uremic syndrome or vascular rejection? Transplant Proc 2000;32:686-687.
31. Winters JL, Pineda AA, McLeod BC, Grima KM. Therapeutic apheresis in renal and metabolic diseases. J Clin Apheresis 2000;15:53-73.
32. Dundas S, Murphy J, Soutar RL, et al. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 1999;354:1327-1330.
33. Carter AO, Borczyk AA, Carlson JAC, et al. A severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. N Engl J Med 1987;24:1496-500.
34. Pichette V, Querin S, Schurch W, et al. Familial hemolytic uremic syndrome and homozygous factor H deficiency. Am J Kidney Dis 1994;24:936-941.
35. Warwicker P, Goodship THJ, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998;53:836-844.
36. Riggenenti P, Remuzzi G. Treatment of adult hemolytic-uremic syndrome. Adv Nephrol Necker Hosp 2000;30:83-94.
37. Singh N, Gayowski T, Marino I. Hemolytic uremic syndrome in solid-organ transplant recipients. Transpl Int 1996;9:68-75.
38. Humar A, Jessurun J, Sharp HL, et al. Thrombotic microangiopathy after liver-small bowel transplant. Clin Transplant 1998;12:600-601.
39. Van Buren D, Van Buren CT, Flechner SM, et al. De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery 1985;98:54-62.
40. Franz M, Regele H, Schmaldienst S, et al. Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy? Transplantation 1998;66:1258-1262.
41. Myers JN, Shabshab SF, Burton NA, et al. Successful use of cyclosporine in a lung transplant recipient with tacrolimusassociated hemolytic uremic syndrome. J Heart Lung Transplant 1999;18:1029-1026.
42. McGregor DO, Robson RA, Lynn KL. Haemolytic-uremic syndrome in a renal transplant recipient treated by conversion to mycophenolate mofetil. Nephron 1998;80:365-366.
43. Brown Z, Neild GH, Willoughby JJ, Somia NV, Cameron SJ. Increased Factor VIII as an index of vascular injury in cyclosporine nephrotoxicity. Transplantation 1986:42:150-153.
44. Yoshida M, Kozaki M, loya N, et al. Plasma thrombomodulin levels as an indicator of vascular injury caused by cyclosporine nephrotoxicity. Transplantation 1990;50:1066-1069.
45. Zoja K, Furci L, Ghilardi F, et al. Cyclosporin-induced endothelial cell injury. Laboratory Investigation 1985;55:455-462.
46. Grace AA, Barradas MA, Mikhailidis DP, Jeremy JY, et al. Cyclosporine A enhances platelet aggregation. Kid Int 1987;32:889-895.